Descartes-08 in Autoantibody Myositis

Part of paid clinical trials in Chapel Hill, North Carolina.

Sponsor
Cartesian Therapeutics
Study ID
NCT07391605
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Antisynthetase Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Descartes-08 — DRUG
    Autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA)
  • Placebo — OTHER
    Plasma-Lyte

Study Details

This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).

Key Dates

Start date
Apr 28, 2026
Status verified
Apr 2026
Primary completion
Nov 30, 2027
Completion
May 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Decartes-08
  • Placebo Comparator: Placebo

Primary Outcome Measure

Major improvement of 2016 ACR/EULAR Total Improvement score [ Time Frame: 24 weeks ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
T13Chapel HillNorth Carolina27599-
T23AustinTexas78759-

Find similar trials in Chapel Hill, NC

By research site
T13· Chapel Hill, NCT23· Austin, TX

Related Studies